Novo Nordisk unveiled fresh findings at a prominent medical conference, indicati...
Selecta Biosciences is embarking on a strategic collaboration with Cartesian, st...
After last year’s nod, AstraZeneca’s flagship PD-L1 Imfinzi is demonstrating eff...
Astellas Pharmaceuticals made a substantial $5.9 billion investment earlier this...
Newly released findings from Vor Bio showcase the effective integration of their...
AstraZeneca is reentering the obesity drug market through a strategic acquisitio...
Owlet, the innovative baby monitoring system company, is celebrating a significa...
Salix Pharmaceuticals, a subsidiary of Bausch Health, has emerged victorious in ...
Atara Biotherapeutics is looking to Pierre Fabre Laboratories, the same collabor...
BD (Becton, Dickinson and Company) is making progress toward its objective of of...
Medeor Therapeutics’ MDR-101 is a single-dose cell therapy designed to revolutio...
Kronos Bio, following promising outcomes in an initial evaluation of a phase 1/2...
In a surprising turn of events, AstraZeneca’s once-forgotten drug, zibotentan, h...
FDA advisers have expressed contentment with CRISPR Therapeutics and Vertex Phar...
C4 Therapeutics has made the decision to discontinue the development of one of i...
Over three years following the initial approval of a pharmaceutical by Deciphera...
